Kexing Biopharm Co., Ltd. (688136.SS) SHH
19.96
-0.22(-1.09%)
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
Kexing Biopharm Co., Ltd.
Sector
Healthcare
Industry
Biotechnology
Employees
1407
First IPO Date
December 14, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Yanqing Zhao | Chief Executive Officer, GM & Director | 0 | 1982 |
| Hui Ming Li | Deputy General Manager of the New Drug Research Center | 0 | 1970 |
| Ke Shao | Deputy General Manager | 0 | 1971 |
| Hongjie Ma | Deputy GM & GM of Technology Center | 0 | 1971 |
| Ning Cui | Deputy GM & Director | 0 | 1977 |
| Wei Shang | Senior Manager of cell biology - New Drug Research Center | 0 | 1986 |
| Xiaoqin Wang | Chief Financial Officer, Secretary to the Board & Director | 0 | 1977 |
| Suofu Qin | Deputy General Manager | 0 | 1964 |
| Shu Ling Wang | Accounting Supervisor | 0 | N/A |
| Fang Fang Tian | Head of the scientific research management center of the pharmaceutical research institute | 0 | 1985 |
Description
Kexing Biopharm Co., Ltd. engages in the research and development, production, and sale of recombinant protein drugs and microbial preparations in China and internationally. The company focuses on pharmaceutical research in the therapeutic fields of antiviral, tumor and immunity, blood, digestion, and degenerative diseases. Its products include recombinant human interferon a1b, human erythropoietin, and human granulocyte stimulating factor; Clostridium butyricum combined live bacteria powder; Kehuang Capsule, a Chinese patent medicine; Entecavir, a chemical drug; and liraglutide, a human glucagon-like peptide-1, as well as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. The company was founded in 1989 and is based in Jinan, China.
